研究者業績
  1. 研究者検索結果一覧
  2. 小林 欣夫

小林 欣夫

コバヤシ ヨシオ  (Yoshio Kobayashi)

基本情報

所属
千葉大学 大学院医学研究院循環器内科学 教授
学位
博士(医学）(千葉大学)
J-GLOBAL ID
200901031812437900
researchmap会員ID
5000068706

研究キーワード

 1

研究分野

 1

経歴

 2

論文

 881
  • Masae Uehara, Hiroyuki Takaoka, Koya Ozawa, Yoshio Kobayashi, Nobusada Funabashi
    INTERNATIONAL JOURNAL OF CARDIOLOGY 168(1) 352-356 2013年9月  査読有り
    Purpose: We evaluated the clinical significance of fat infiltration in the moderator-band (MB) of the right ventricle (RV) and in the RV myocardium (RVM) and its association with conduction abnormalities in the electrocardiogram. Materials and methods: 132 subjects (58 male; age 59 +/- 27 years) with no findings of organic-disease (all right and left side hearts were normal) undergoing electrocardiogram-gated non-contrast multislice-CT (Light-Speed-Ultra-16) were retrospectively analyzed for the presence of fat infiltrating the MB or RVM. Results: MB fat infiltration was detected in 42 subjects, but these individuals showed no significant differences in the incidence of right bundle branch-block, mean QRS-width or standard-deviation of the QRS-axis, which would have suggested the presence of hemi left bundle branch-block. Only age (64.3 vs 57.9 years, p=0.025) was significantly different in subjects with MB fat infiltration. But logistic regression showed none of the factor associated with increased presence of MB fat infiltration. RVM fat infiltration was detected in 35 subjects, again with no significant differences in the incidence of right bundle branch-block, QRS-width or standard-deviation of the QRS axis. Only age (65.9 vs 57.8 years, p=0.001) and gender (71% vs 51% female, p=0.033) were significantly different in subjects with RVM fat infiltration. Logistic regression showed age (Odd-ratio=1.05 and 95% CI=1.01-1.08 p=0.008) and female sex (Odd-ratio=2.44 and 95% CI=1.03-5.88; p=0.043) were associated with increased RV fat infiltration. Conclusions: MB or RVM fat infiltration seen on CT may not indicate organized abnormal myocardial conduction, but RVM fat infiltration may indicate only degeneration due to aging, especially in females. (c) 2012 Elsevier Ireland Ltd. All rights reserved.
  • Koya Ozawa, Nobusada Funabashi, Hiroyuki Takaoka, Masae Uehara, Yoshio Kobayashi
    INTERNATIONAL JOURNAL OF CARDIOLOGY 168(2) 1472-1478 2013年9月  査読有り
    Purpose: If specific organized substrates of ventricular-fibrillation (VF) are identified, they may provide important-information for prevention of sudden-cardiac-death. To identify specific organized substrates of VF, we compared 320-slice CT heart images in non-ischemic VF subjects with non-ischemic sustained and non-sustained ventricular-tachycardia (VT) subjects. Materials and methods: Retrospective analysis of a total of 103 subjects who had VF (17 subjects; age, 59 +/- 16 years), sustained VT (20 subjects; 62 +/- 19 years), or non-sustained VT (66 subjects; 60 +/- 15 years) underwent 320-slice CT (Aquilion one). Results: After excluding 26 ischemic subjects with >50% stenosis in any coronary arteries on CT, myocardial infarction, or coronary vasospastic angina, a total of 77 non-ischemic subjects (12 VF subjects; age, 58 +/- 18 years), (13 sustained VT subjects; 55 +/- 20 years) or (52 non-sustained VT subjects; 58 +/- 15 years) were analyzed. On CT, myocardial abnormal-late-enhancement was significantly more frequent in the VF group (75%, all myocardial abnormal-late-enhancement in left-ventricle) than in the sustained VT group (31%) and the non-sustained VT group (35%) (both P<0.01). Myocardial fatty change was significantly more frequent in the sustained VT group (54%) than in the VF group (17%) and the non-sustained VT group (12%) (both P<0.01). Final diagnoses of the non-ischemic VF and sustained groups included four subjects in each case with normal cardiac structure on transthoracic echocardiogram; the former included two subjects who had abnormal-late-enhancement on CT without specific ECG findings. Conclusions: Myocardial abnormal-late-enhancement and fatty change on CT may be substrates of VF or sustained VT in non-ischemic subjects. 320-slice CT can evaluate both coronary arteries and myocardium. (c) 2013 Elsevier Ireland Ltd. All rights reserved.
  • Nobusada Funabashi, Ryosuke Irie, Miki Aiba, Ryo Morimoto, Toru Kabashima, Shota Fujii, Masae Uehara, Koya Ozawa, Hiroyuki Takaoka, Yoshio Kobayashi
    INTERNATIONAL JOURNAL OF CARDIOLOGY 168(1) 601-603 2013年9月  査読有り
  • Naoko Mizuno, Nobusada Funabashi, Hiroyuki Takaoka, Yoshio Kobayashi
    INTERNATIONAL JOURNAL OF CARDIOLOGY 168(1) 594-595 2013年9月  査読有り
  • Masataka Yokoyama, Yoshio Kobayashi, Tohru Minamino
    CIRCULATION RESEARCH 113(4) 2013年8月  査読有り
  • Masae Uehara, Hiroyuki Takaoka, Yoshio Kobayashi, Nobusada Funabashi
    INTERNATIONAL JOURNAL OF CARDIOLOGY 167(3) 809-815 2013年8月  査読有り
    Purpose: To evaluate the diagnostic accuracy of 320-slice CT for detection of significant coronary artery stenosis in patients with various heart rates (HR) and heart rhythms, including tachycardia and chronic atrial-fibrillation (CAF) compared with conventional-coronary-angiography (CAG). Materials and methods: One-hundred-six consecutive patients underwent both 320-slice CT and CAG within 3 months (normal-sinus-rhythm [NSR] 91.5%, CAF 8.5%, mean HR 65 +/- 15 beats/min). There were no cardiac events between the 2 procedures. Patients were divided in 2 groups: Group 1 (HR <65 with NSR at CT scan, n = 62), and Group 2 (HR > 64 with NSR or heart rhythm irregularities at CT scan, n = 44). Patients with > 50% or > 75% luminal stenosis on CT were compared with those with > 50% or > 75% stenosis on CAG, respectively. Results: In a segment-by-segment analysis, in all patients, sensitivity, specificity, positive (PPV) and negative predictive value (NPV) of > 50% stenosis on CT for predicting > 50% stenosis on CAG were 69, 98, 78, and 97%, respectively, and those of > 75% stenosis on CT for predicting > 75% stenosis on CAG were 78, 98, 64, and 99%, respectively. Sensitivity, specificity, PPV, and NPV of > 50% and 75% stenosis on CT for predicting > 50% and > 75% stenosis, respectively, on CAG were comparable. Diagnostic accuracy was essentially the same in both groups. Conclusion: 320-slice CT had high diagnostic accuracy for the detection of significant coronary artery stenosis compared with CAG. Even though the numbers were small, patients with high HR or heart rhythm irregularities might have essentially equivalent results to those with low HR with NSR. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
  • Maiko Takahashi, Nobuhiro Harada, Yuka Isozaki, Kwangho Lee, Rei Yajima, Akihisa Kataoka, Mariko Saito, Akiyo Kanaeda, Chiharu Yamaguchi, Tomoko Kamata, Koya Ozawa, Akiko Tani, Sawako Horie, Tomoko Umazume, Yoshio Kobayashi, Nobusada Funabashi
    INTERNATIONAL JOURNAL OF CARDIOLOGY 167(4) 1625-1631 2013年8月  査読有り
    Purpose: To evaluate the efficiency of automated function imaging (AFI) on transthoracic echocardiogram (TTE) for detecting left ventricular (LV) wall motion (LVWM) abnormalities, we compared longitudinal peak systolic strain (LPSS) measurements using AFI with naked eye TTE evaluations by experienced cardiologists and non-experienced residents. Materials and methods: A total of 352 segments of LV myocardium from 22 consecutive subjects with LVWM abnormalities based on American Heart Association classifications (11 male, mean age 58 +/- 14 years) on previous TTE (Vivid-7, GE) were evaluated. LPSS was measured using stored AFI data. Naked eye evaluation of LVWM was performed by 2 experienced cardiologists and 2 non-experienced residents. Results: AFI successfully tracked 342 (97%) of all segments (mean LPSS -14.8 +/- 8.1%). A significant strong negative correlation was observed between LV ejection fraction using method of disks and global LPSS (R=-0.8974). Temporary AFI criteria of LPSS were normal <-12; hypokinesis -12-2; and akinesis >2. Of 342 segments, 239, 87, and 16 segments were diagnosed as normal, hypokinesis, and akinesis, respectively. Level of agreement and kappa coefficients between qualitative evaluation of LVWM by AFI temporary criteria and qualitative evaluation of LVWM by experienced cardiologist 2 (0.784 and 0.479, respectively) were inferior to those comparing experienced cardiologists (0.845 and 0.595) but superior comparing experienced cardiologist with non-experienced resident (0.696 and 0.323), and between the 2 non-experienced-residents (0.682 and 0.347). Conclusion: Qualitative evaluation of LVWM using temporary AFI criteria had a 97% success rate and agreed well with findings of an experienced cardiologist. AFI can be a useful tool for training residents. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
  • Aika Nojima, Masakatsu Yamashita, Yohko Yoshida, Ippei Shimizu, Harumi Ichimiya, Naomi Kamimura, Yoshio Kobayashi, Shigeo Ohta, Naoaki Ishii, Tohru Minamino
    PLoS ONE 8(7) e69178 2013年7月30日  査読有り
    There is increasing evidence that nutrient-sensing machinery is critically involved in the regulation of aging. The insulin/insulin-like growth factor-1 signaling pathway is the best-characterized pathway with an influence on longevity in a variety of organisms, ranging from yeast to rodents. Reduced expression of the receptor for this pathway has been reported to prolong the lifespan however, the underlying mechanisms are largely unknown. Here we show that haploinsufficiency of Akt1 leads to an increase of the lifespan in mice. Akt1+/- mice had a lower body weight than their littermates with less fat mass and normal glucose metabolism. Ribosomal biogenesis and the mitochondrial DNA content were significantly reduced in these mice, along with a decrease of oxidative stress. Consistent with the results obtained in mice, inhibition of Akt-1 promoted longevity in nematodes (Caenorhabditis elegans), whereas activation of Akt-1 shortened the lifespan. Inhibition of Akt-1 led to a decrease of ribosomal gene expression and the mitochondrial DNA content in both human cells and nematodes. Moreover, deletion of ribosomal gene expression resulted in a decrease of the mitochondrial DNA content and normalized the lifespan shortened by Akt-1 activation in nematodes. These results suggest that an increase of mitochondrial amount and energy expenditure associated with enhanced protein synthesis accelerates both aging and the onset of age-associated diseases. © 2013 Nojima et al.
  • Hiroyuki Takaoka, Nobusada Funabashi, Michiko Daimon, Koki Nakamura, Masae Uehara, Yoshio Kobayashi
    International Journal of Cardiology 166(2) e25-e27 2013年6月20日  査読有り
  • Hiroyuki Takaoka, Nobusada Funabashi, Hiroyuki Takano, Hideyuki Miyauchi, Akihisa Kataoka, Masae Uehara, Yoshio Kobayashi
    INTERNATIONAL JOURNAL OF CARDIOLOGY 166(1) E19-E20 2013年6月  査読有り
  • Tomoko Umazume, Nobusada Funabashi, Toshihisa Inoue, Takeshi Nishi, Taro Shimizu, Kigen Jo, Takayasu Ishikawa, Yasutake Nakamura, Akira Miyazaki, Yoshio Kobayashi
    INTERNATIONAL JOURNAL OF CARDIOLOGY 165(3) 551-555 2013年5月  査読有り
  • Hideki Kitahara, Yoshihide Fujimoto, Keishi Ishikawa, Yasuhiro Aoki, Yo Iwata, Tadayuki Kadohira, Tomoki Morino, Kenji Ohkubo, Kazumasa Sugimoto, Yoshio Kobayashi
    ANGIOLOGY 64(3) 211-215 2013年4月  査読有り
    Whether endothelial dysfunction after sirolimus-eluting stent (SES) implantation is persistent has not been fully evaluated. Endothelial function was evaluated in 152 lesions that underwent follow-up coronary angiography after SES implantation. Lesions were classified into 2 groups according to the duration between SES implantation and follow-up: <= 12 months (n = 95) and >12 months (n = 57). Changes in coronary diameter in response to 10(-8) mol/L (-2.4% +/- 6.3% vs -4.9% +/- 3.8%, P < .01) and 10(-7) mol/L acetylcholine (Ach; -4.6% +/- 7.6% vs -10.7% +/- 9.1%, P < .001) in segment proximal to SES were significantly attenuated in the >12-month group than in the <= 12-month group. There were less changes in coronary diameter in response to 10(-8) mol/L (-2.3% +/- 4.6% vs -6.9% +/- 5.0%, P < .001) and 10(-7) mol/L Ach (-6.5% +/- 11.4% vs -16.8% +/- 10.5%, P < .001) in segment distal to SES in the >12-month group. Endothelial dysfunction may diminish long after SES implantation.
  • Hiroyuki Takano, Hiroshi Mizuma, Yoichi Kuwabara, Yasunori Sato, Satoshi Shindo, Norihiko Kotooka, Daisuke Fujimatsu, Yoshio Kobayashi, Teruo Inoue, Koichi Node, Issei Komuro
    CIRCULATION JOURNAL 77(4) 917-925 2013年4月  査読有り
    Background: Recent clinical trials using rosuvastatin, a hydrophilic statin, did not show beneficial effects on cardiovascular events in patients with heart failure. We examined the cardioprotective effects of pitavastatin, a lipophilic statin, on Japanese patients with chronic heart failure (CHF). Methods and Results: A total of 574 Japanese patients with CHF were randomly assigned to the pitavastatin group (n=288) or the control group (n=286). There was no significant difference between the 2 groups for the primary outcome, which was a composite of cardiac death and hospitalization for worsening HF (adjusted hazard ratio (aHR): 0.922, 95% confidence interval (Cl): 0.632-1.345, P=0.672). A strongly significant statistical interaction between the effect of pitavastatin and left ventricular ejection fraction (LVEF) was found (P=0.004). In patients with LVEF >= 30%, a significant reduction in the primary outcome (aHR: 0.525, 95% Cl: 0.308-0.896, P=0.018) was observed in the pitavastatin group. Pitavastatin did not show any effects on the primary outcome (aHR: 1.582, 95% CI: 0.890-2.813, P=0.118) in the subgroup of patients with LVEF <30%. Conclusions: Pitavastatin did not reduce cardiac death or hospitalization for worsening HF in Japanese patients with CHF. (UMIN-ID: UMINC000000428). (Ciro J 2013; 77: 917-925)
  • Kobayashi Y, Iwata A, Suzuki K, Suto A, Kawashima S, Saito Y, Owada T, Kobayashi M, Watanabe N, Nakajima H
    Proceedings of the National Academy of Sciences of the United States of America 110(13) 5121-5126 2013年3月  査読有り
  • Yo Iwata, Yoshihide Fujimoto, Tomoki Morino, Kazumasa Sugimoto, Kenji Ohkubo, Tadayuki Kadohira, Kenichi Fukushima, Hideki Kitahara, Issei Komuro, Yoshio Kobayashi
    AMERICAN HEART JOURNAL 165(3) 408-414 2013年3月  査読有り
    Background Stem cell mobilization by granulocyte colony-stimulating factor (G-CSF) has been shown to enhance endothelial healing after spontaneous or iatrogenic arterial disruption. Granulocyte colony-stimulating factor treatment might attenuate endothelial dysfunction after sirolimus-eluting stent (SES) implantation that may be associated with adverse cardiac events during follow-up. This prospective, double-blind, randomized, placebo-controlled study investigated whether G-CSF improved endothelial dysfunction after SES implantation. Methods One hundred patients who underwent SES implantation were randomly assigned to the G-CSF (n = 50) or the placebo group (n = 50). They received daily subcutaneous injection of 300 mu g G-CSF or saline for 5 days. Endothelial function was estimated by measuring the coronary vasoreactivity in the segments 15 mm proximal and distal to SES in response to intracoronary infusion of acetylcholine (10(-8) and 10(-7) mol/L) at 9-month follow-up. Results Follow-up angiography was performed in 41 G-CSF patients (82%) and 46 placebo patients (92%) (P =.14). Changes in coronary diameter in response to acetylcholine infusion in the proximal segment were not significantly different between the 2 groups. However, vasoconstriction in the distal segment in response to 10(-8) mol/L (-3.9% +/- 6.4% vs -7.0% +/- 8.1%, P < .05) and 10(-7) mol/L (-8.8% +/- 11.0% vs -15.2% +/- 7.6%, P < .01) acetylcholine infusion was attenuated in the G-CSF group. Endothelium-independent vasodilatation after nitrate infusion did not differ between the 2 groups. Conclusion Granulocyte colony-stimulating factor attenuates endothelial dysfunction after SES implantation. (Am Heart J 2013;165:408-14.)
  • Okada Sho, Odaka Kenichi, Zhang Ming-Rong, Tadokoro Hiroyuki, Yui Joji, Wakizaka Hidekatsu, Xie Lin, Uchino Yoshio, Kawamura Kazunori, Kumata Katsushi, Komuro Issei, Minamino Tohru, Kobayashi Yoshio
    CIRCULATION 126(21) 2012年11月20日  査読有り
  • H. Takano, H. Hasegawa, H. Narumi, S. Shindo, H. Mizuma, Y. Kuwabara, Y. Kobayashi, I. Komuro
    Journal of Human Hypertension 26(11) 656-663 2012年11月  査読有り
    The Valsartan Amlodipine Randomized Trial (VART) was performed to compare the beneficial effects of valsartan and amlodipine on cardiovascular events in Japanese hypertensive patients. In this subanalysis of the VART, we assessed the relationship between home blood pressure (HBP) levels and cardiovascular events in the enrolled patients. We enrolled 1021 patients with mild-to-moderate hypertension in the VART. The participants were allocated randomly to either the valsartan group or the amlodipine group. The primary end point was a composite of all-cause death, sudden death, cerebrovascular events, cardiac events, vascular events and renal events. A total of 621 patients (valsartan group: 305 and amlodipine group: 316) completed the measurements of HBP (morning and evening) throughout the trial. Both the agents evenly and significantly lowered morning HBP and evening HBP throughout the trial. There was no significant difference in the primary end point between the two groups. However, we observed significant decreases in the left ventricular mass index and urinary albumin to creatinine ratio in the valsartan group but not in the amlodipine group. There were no significant differences in HBP levels and the main outcome of the cardiovascular events between the valsartan and amlodipine groups. However, in the valsartan group, significant improvements in left ventricular hypertrophy and microalbuminuria were observed. © 2012 Macmillan Publishers Limited All rights reserved.
  • Ippei Shimizu, Yohko Yoshida, Junji Moriya, Taro Katsuno, Masayoshi Suda, Yoshio Kobayashi, Tohru Minamino
    CIRCULATION 126(21) 2012年11月  査読有り
  • Yohko Yoshida, Tohru Minamino, Kaoru Tateno, Ippei Shimizu, Sho Okada, Masataka Yokoyama, Takashi Ito, Aika Nojima, Taro Katsuno, Atsushi Nakagomi, Masayoshi Suda, Yoshio Kobayashi
    CIRCULATION 126(21) 2012年11月  査読有り
  • Masataka Yokoyama, Tohru Minamino, Sho Okada, Atsushi Nakagomi, Kaoru Tateno, Ippei Shimizu, Aika Nojima, Takashi Ito, Yohko Yoshida, Taro Katsuno, Issei Komuro, Yoshio Kobayashi
    CIRCULATION 126(21) 2012年11月  査読有り
  • Yoshio Kobayashi
    Journal of Cardiology Cases 6(4) e124-e125 2012年10月  査読有り
  • 上原 雅恵, 船橋 伸禎, 堀江 佐和子, 高岡 浩之, 小澤 公哉, 小林 欣夫
    脈管学 52(Suppl.) S107-S107 2012年9月  
  • Yoshihide Fujimoto, Yuji Matsudo, Yoshio Kobayashi
    JOURNAL OF INVASIVE CARDIOLOGY 24(9) E199-E201 2012年9月  査読有り
    Deployment of a polytetrafluoroethylene-covered stent is a useful option to seal coronary perforation. However, the high profile and low flexibility compromise its deliverability. To facilitate stent delivery, deep-vessel intubation with a 5 Fr guiding catheter through a 6 or 7 Fr guiding catheter (mother-and-child catheter) has been used. This case report describes a successful deployment of a polytetrafluoroethylene-covered stent through a 5 Fr Heartrail ST01 guiding catheter (Terumo) to seal coronary perforation. J INVASIVE CARDIOL 2012; 24(9): E199-E201
  • 上原 雅恵, 船橋 伸禎, 堀江 佐和子, 高岡 浩之, 小澤 公哉, 小林 欣夫
    日本心臓病学会誌 7(Suppl.I) 323-323 2012年8月  
  • 堀江 佐和子, 船橋 伸禎, 上原 雅恵, 高岡 浩之, 小澤 公哉, 小林 欣夫
    日本心臓病学会誌 7(Suppl.I) 334-334 2012年8月  
  • 片岡 明久, 船橋 伸定, 堀江 佐和子, 高岡 浩之, 上原 雅恵, 小林 欣夫
    日本心臓病学会誌 7(Suppl.I) 181-181 2012年8月  
  • 高岡 浩之, 船橋 伸禎, 上原 雅恵, 小澤 公哉, 片岡 明久, 小林 欣夫
    日本心臓病学会誌 7(Suppl.I) 262-262 2012年8月  
  • 高岡 浩之, 船橋 伸禎, 上原 雅恵, 小澤 公哉, 大門 道子, 片岡 明久, 小林 欣夫
    日本心臓病学会誌 7(Suppl.I) 322-322 2012年8月  
  • Ippei Shimizu, Tohru Minamino, Yohko Yoshida, Taro Katsuno, Issei Komuro, Yoshio Kobayashi
    CIRCULATION RESEARCH 111(4) 2012年8月  査読有り
  • Sho Okada, Masataka Yokoyama, Haruhiro Toko, Kaoru Tateno, Junji Moriya, Ippei Shimizu, Aika Nojima, Takashi Ito, Yohko Yoshida, Yoshio Kobayashi, Hideki Katagiri, Tohru Minamino, Issei Komuro
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY 32(8) 1902-1909 2012年8月  査読有り
    Objective-The central nervous system is thought to influence the regulation of the cardiovascular system in response to humoral and neural signals from peripheral tissues, but our understanding of the molecular mechanisms involved is still quite limited. Methods and Results-Here, we demonstrate a central nervous system-mediated mechanism by which brain-derived neurotrophic factor (BDNF) has a protective effect against cardiac remodeling after myocardial infarction (MI). We generated conditional BDNF knockout mice, in which expression of BDNF was systemically reduced, by using the inducible Cre-loxP system. Two weeks after MI was induced surgically in these mice, systolic function was significantly impaired and cardiac size was markedly increased in conditional BDNF knockout mice compared with controls. Cardiomyocyte death was increased in these mice, along with decreased expression of survival molecules. Deletion of the BDNF receptor (tropomyosin-related kinase B) from the heart also led to the exacerbation of cardiac dysfunction after MI. The plasma levels of BDNF were markedly increased after MI, and this increase was associated with the upregulation of BDNF expression in the brain, but not in the heart. Ablation of afferent nerves from the heart or genetic disruption of neuronal BDNF expression inhibited the increase of plasma BDNF after MI and led to the exacerbation of cardiac dysfunction. Peripheral administration of BDNF significantly restored the cardiac phenotype of neuronal BDNF-deficient mice. Conclusion-These results suggest that BDNF expression is upregulated by neural signals from the heart after MI and then protects the myocardium against ischemic injury. (Arterioscler Thromb Vasc Biol 2012;32:1902-1909.)
  • Akihisa Kataoka, Takatsugu Kajiyama, Yukiko Ozawa, Masashi Kabasawa, Goro Matsumiya, Yoshio Kobayashi, Nobusada Funabashi
    INTERNATIONAL JOURNAL OF CARDIOLOGY 158(1) E11-E12 2012年6月  査読有り
  • Nehiro Kuriyama, Yoshio Kobayashi, Yoshisato Shibata
    Journal of Cardiology Cases 5(3) e137-e139 2012年6月  査読有り
    This case report demonstrates iatrogenic left main coronary artery dissection during percutaneous coronary intervention. Intravascular ultrasound imaging showed that the entry site of the false lumen was located at the cranial part of the ostium of the left main coronary artery. Utilizing this information, the operator was able to achieve the guidewire entering into the true lumen. © 2012 Japanese College of Cardiology.
  • Ippei Shimizu, Yohko Yoshida, Taro Katsuno, Kaoru Tateno, Sho Okada, Junji Moriya, Masataka Yokoyama, Aika Nojima, Takashi Ito, Rudolf Zechner, Issei Komuro, Yoshio Kobayashi, Tohru Minamino
    CELL METABOLISM 15(5) 787-787 2012年5月  査読有り
  • Akihisa Kataoka, Hiroyuki Takano, Taro Imaeda, Kwangho Lee, Marehiko Ueda, Nobusada Funabashi, Shigeto Oda, Issei Komuro, Yoshio Kobayashi
    INTERNATIONAL JOURNAL OF CARDIOLOGY 157(2) E33-E34 2012年5月  査読有り
  • Raita Uchiyama, Hiroshi Hasegawa, Yoshihito Kameda, Kazutaka Ueda, Yoshio Kobayashi, Issei Komuro, Hiroyuki Takano
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY 52(5) 1038-1047 2012年5月  査読有り
    We and others have previously reported that granulocyte colony-stimulating factor (G-CSF) prevents left ventricular remodeling and dysfunction after myocardial infarction in animal models and human. We have also reported that G-CSF inhibits the progression of atherosclerosis in animal models, but its precise mechanism is still elusive. So, we examined the effects of G-CSF on atherosclerosis in apolipoprotein E-deficient (ApoE(-/-)) mice. Twelve-week-old male ApoE(-/-) mice were subcutaneously administrated with 200 mu g/kg of G-CSF or saline once a day for 5 consecutive days per a week for 4 weeks. Atherosclerotic lesion of aortic sinus was significantly reduced in the G-CSF-treated mice compared with the saline-treated mice (35% reduction, P<0.05). G-CSF significantly reduced the expression level of interferon-gamma by 31% and increased the expression level of interleukin-10 by 20% in atherosclerotic lesions of aortic sinus. G-CSF increased the number of CD4(+)CD25(+) regulatory T cells in lymph nodes and spleen, and enhanced the suppressive function of regulatory T cells in vitro. G-CSF markedly increased the number of Foxp3-positive regulatory T cells in atherosclerotic lesions of aortic sinus. Administration of anti-CD25 antibody (PC61) that depletes regulatory T cells abrogated these ather-oprotective effects of G-CSF. Moreover, in ApoE(-/-)/CD28(-/-) mice, that lack regulatory T cells, the protective effects of G-CSF on atherosclerosis were not recognized. These findings suggest that regulatory T cells play an important role in the ather-oprotective effects of G-CSF. (C) 2012 Elsevier Ltd. All rights reserved.
  • Yoshihito Kameda, Hiroshi Hasegawa, Akihiko Kubota, Hiroyuki Tadokoro, Yoshio Kobayashi, Issei Komuro, Hiroyuki Takano
    CIRCULATION JOURNAL 76(5) 1159-1168 2012年5月  査読有り
    Background: 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins), which are widely used to lower plasma cholesterol levels, have been reported to have various pleiotropic effects such as protective effect of endothelial cells, angiogenic effect, antioxidant effect and anti-inflammatory effect. It is unclear, however, whether statins have any effects on the progression from left ventricular (LV) hypertrophy to heart failure in the established hypertrophied heart. Methods and Results: C57BL/6 mice were treated with pitavastatin (pitava) or vehicle (control) from 2 weeks (established hypertrophy stage) after transverse aortic constriction (TAC) and the treatment was continued for 4 weeks. Pitavastatin significantly inhibited the progression from LV hypertrophy to heart failure as assessed on echocardiography. The cardiomyocyte cross-sectional area was significantly increased in the control group compared to the sham-operated mice (sham group), but it was not significantly different between the control group and the pitava group at 6 weeks after TAG. Moreover, pitavastatin induced myocardial angiogenesis (ratio of number of endothelial cells to cardiomyocytes) and decreased the myocardial fibrosis and oxidative stress. The expression of angiopoietin-1 in the heart was significantly increased by pitavastatin at 6 weeks after TAG. Conclusions: Pitavastatin has preventive effects on the progression of heart failure even in the hypertrophied heart. (Circ J 2012; 76: 1159-1168)
  • Yoshihide Fujimoto, Yoshio Kobayashi, Masashi Yamaguchi
    JACC-CARDIOVASCULAR INTERVENTIONS 5(3) E5-E6 2012年3月  査読有り
  • Eiji Ichimoto, Yoshihide Fujimoto, Kenichirou Kubo, Tomoaki Miyayama, Yo Iwata, Hideki Kitahara, Yoshio Kobayashi
    JOURNAL OF INVASIVE CARDIOLOGY 24(2) 55-57 2012年2月  査読有り
    Objectives. The present study evaluated the mechanism of edge restenosis after sirolimus-eluting stent (SES) implantation using serial (post-intervention and follow-up) intravascular ultrasound (IVUS) analysis. Background. There is little information about the mechanism of edge restenosis after SES implantation. Methods. Serial IVUS analysis was performed at 5 mm reference segments immediately proximal and distal to the SES in 25 lesions with edge restenosis. Proximal and distal reference segments were divided into 1 mm subsegments. Results. Between post-intervention and follow-up IVUS studies, a decrease in external elastic membrane area was observed at the proximal edge. There was a significant increase in plaque & media area in the subsegment closest to the proximal edge. On the other hand, there was an increase in plaque & media area at the distal edge, with no change in external elastic membrane area. Conclusions. There may be different mechanisms between proximal and distal edge restenosis after SES implantation. Negative remodeling plays a major role in proximal edge restenosis. On the other hand, intimal hyperplasia may mainly contribute to distal edge restenosis.
  • 小笹 由香子, 赤澤 宏, 永井 敏雄, 小林 欣夫, 小室 一成
    血管 35(1) 30-30 2012年1月  
  • 古賀 俊輔, 長谷川 洋, 康田 典鷹, 李 光浩, 上田 希彦, 船橋 伸禎, 有村 卓, 木村 彰方, 永井 敏雄, 小林 欣夫
    心臓 44(11) 1399-1404 2012年  
    症例は43歳，男性．幼少時より心電図異常を指摘されていた．某年6月某日，自宅安静時に突然意識を消失し，家族により心肺蘇生が施行され，救急隊により自動体外式除細動器(automated external defibrillator；AED)で除細動され洞調律に復帰し，前医へ搬送された．第9病日に心室細動(ventricular fibrillation；VF)に対する植込み型除細動器(implantable cardioverter defibrillator；ICD)植え込み目的で当院転院となり，心エコー，心臓CTにて，瘤内血栓を伴う左室心尖部瘤と心室中部閉塞性肥大型心筋症を認め，第12病日にICD植え込み術を施行した．心室内血栓はヘパリンとワルファリンにて消失し，経過良好にて退院となった．心尖部瘤を合併した肥大型心筋症では，文献的にも心室頻拍やVFといった致死的不整脈の出現する危険性が高く，心室中部閉塞性肥大型心筋症に心尖部瘤を伴う症例では突然死や致死性不整脈のリスクが有意に上昇することが知られている．したがって，本症例においてもハイリスクとして管理する必要があり，心尖部瘤を合併した心室中部閉塞性肥大型心筋症では突然死の予防としてICDを積極的に考慮する必要があると考えられた．
  • Ippei Shimizu, Yohko Yoshida, Taro Katsuno, Kaoru Tateno, Sho Okada, Junji Moriya, Masataka Yokoyama, Aika Nojima, Takashi Ito, Rudolf Zechner, Issei Komuro, Yoshio Kobayashi, Tohru Minamino
    CELL METABOLISM 15(1) 51-64 2012年1月  査読有り
    Several clinical studies have shown that insulin resistance is prevalent among patients with heart failure, but the underlying mechanisms have not been fully elucidated. Here, we report a mechanism of insulin resistance associated with heart failure that involves upregulation of p53 in adipose tissue. We found that pressure overload markedly upregulated p53 expression in adipose tissue along with an increase of adipose tissue inflammation. Chronic pressure overload accelerated lipolysis in adipose tissue. In the presence of pressure overload, inhibition of lipolysis by sympathetic denervation significantly downregulated adipose p53 expression and inflammation, thereby improving insulin resistance. Likewise, disruption of p53 activation in adipose tissue attenuated inflammation and improved insulin resistance but also ameliorated cardiac dysfunction induced by chronic pressure overload. These results indicate that chronic pressure overload upregulates adipose tissue p53 by promoting lipolysis via the sympathetic nervous system, leading to an inflammatory response of adipose tissue and insulin resistance.
  • Hiroshi Hasegawa, Hiroyuki Takano, Yoshihito Kameda, Akihiko Kubota, Yoshio Kobayashi, Issei Komuro
    CLINICAL AND EXPERIMENTAL HYPERTENSION 34(2) 86-91 2012年  査読有り
    The Candesartan Cooperative Research of Therapy Design for Early Morning Hypertension in CHIBA was designed to investigate whether switching from angiotensin II receptor blockers (ARBs) except candesartan to candesartan might be effective in Japanese patients with morning hypertension. Seventy-eight mild to moderate hypertensive patients, who were treated with the standard doses of ARBs except candesartan (losartan, 50 mg; valsartan, 80 mg; telmisartan, 40 mg; or olmesartan, 20 mg), were entered into 12-week treatment period with candesartan 8 mg according to a multicenter, open-label design. Morning and office blood pressures (BPs) were significantly reduced (morning, -10.1 +/- 10.5/-4.5 +/- 8.4 mm Hg; office, -13.1 +/- 17.3/-6.2 +/- 11.3 mm Hg) after medication change. Target BPs (morning BPs <= 135/85 mm Hg and office BPs <= 140/90 mm Hg) achievement rates were 42.9% in the morning and 64.3% at office. No adverse events were recognized in all patients. Candesartan treatment significantly reduced the morning and office BPs compared with other ARBs in Japanese patients with morning hypertension.
  • Asano T, Kobayashi Y
    Nihon rinsho. Japanese journal of clinical medicine 69 Suppl 9 475-480 2011年11月  査読有り
  • Sho Okada, Tohru Minamino, Masataka Yokoyama, Kaoru Tateno, Junji Moriya, Ippei Shimizu, Aika Nojima, Takashi Ito, Yoko Ogasawara, Issei Komuro, Yoshio Kobayashi
    CIRCULATION 124(21) 2011年11月  査読有り
  • Kaoru Tateno, Tohru Minamino, Yohko Yoshida, Junji Moriya, Sho Okada, Ippei Shimizu, Masataka Yokoyama, Takashi Ito, Aika Nojima, Issei Komuro, Yoshio Kobayashi
    CIRCULATION 124(21) 2011年11月  査読有り
  • Yohko Yoshida, Tohru Minamino, Kaoru Tateno, Sho Okada, Junji Moriya, Ippei Shimizu, Masataka Yokoyama, Takashi Ito, Aika Nojima, Yoshio Kobayashi
    CIRCULATION 124(21) 2011年11月  査読有り
  • Junji Moriya, Ippei Shimizu, Kaoru Tateno, Sho Okada, Masataka Yokoyama, Aika Nojima, Takashi Ito, Yohko Ogasawara, Issei Komuro, Yoshio Kobayashi, Tohru Minamino
    CIRCULATION 124(21) 2011年11月  査読有り
  • Masataka Yokoyama, Tohru Minamino, Sho Okada, Kaoru Tateno, Junji Moriya, Ippei Shimizu, Aika Nojima, Takashi Ito, Yoko Ogasawara, Issei Komuro, Yoshio Kobayashi
    CIRCULATION 124(21) 2011年11月  査読有り
  • Hiroshi Hasegawa, Hiroyuki Takano, Hiroya Narumi, Masashi Ohtsuka, Tadahiko Mizuguchi, Takao Namiki, Yoshio Kobayashi, Issei Komuro
    HYPERTENSION RESEARCH 34(11) 1179-1184 2011年11月  査読有り
    The Telmisartan and Losartan Cardiac Evaluation Trial, a multicenter, prospective, randomized, open-labeled, blinded-endpoint trial, was designed to compare the effects of two angiotensin II receptor blockers (ARBs), telmisartan and losartan, on cardiovascular protection in Japanese patients with mild to moderate essential hypertension. We compared the effects of telmisartan and losartan on left ventricular (LV) hypertrophy, cardiac function, atherosclerosis of carotid arteries and surrogate markers related to the actions of peroxisome proliferator-activated receptor-gamma. A total of 58 patients were enrolled in the present trial and the follow-up period was 1 year. There were no significant differences in blood pressure (BP) levels between the telmisartan group and the losartan group throughout the trial. The percentage of the patients treated with ARB monotherapy was significantly higher in the telmisartan group compared with the losartan group. In addition, the progression of intima-media thickness of common carotid artery was significantly inhibited in the telmisartan group compared with the losartan group. Neither group experienced significant changes in cardiac function and LV mass index. There were no differences between the groups with respect to changes in surrogate markers such as serum adiponectin, creatinine, homeostasis model assessment index, plasminogen activator inhibitor-1 and high sensitivity C-reactive protein. Although BP levels were equal and well controlled in both groups, telmisartan showed more protective vascular effects than losartan. Hypertension Research (2011) 34, 1179-1184; doi:10.1038/hr.2011.114; published online 28 July 2011
  • Tadayuki Kadohira, Yoshio Kobayashi, Yo Iwata, Hideki Kitahara, Issei Komuro
    ANGIOLOGY 62(5) 397-400 2011年7月  査読有り
    There is little information about coronary artery endothelial dysfunction in patients with sleep apnea. We evaluated relation between severity of sleep apnea and coronary artery endothelial dysfunction. In all, 26 patients without significant coronary stenoses were enrolled. Endothelial function was estimated by measuring coronary vasoreactivity in response to acetylcholine infusion (10(-7) mol/L) into coronary arteries. Vasoconstriction rate was defined as ([lumen diameter after isosorbide dinitrate injection - lumen diameter after acetylcholine injection]/lumen diameter after isosorbide dinitrate injection x 100). Vasoconstriction rate was calculated at each major coronary artery and the highest value was used for that patient. Overnight sleep study was performed and the apnea-hypopnea index (AHI) was calculated as the mean number of apneas and hypopneas per hour of sleep. There was significant correlation between AHI and vasoconstriction rate (P=.04). There is significant correlation between severity of sleep apnea and endothelial function of coronary arteries.

MISC

 395
  • Yuichi Saito, Yoshio Kobayashi, Kenichi Tsujita, Koichiro Kuwahara, Yuji Ikari, Hiroyuki Tsutsui, Koichiro Kinugawa, Ken Kozuma
    Circulation Journal 88(11) 1727-1736 2024年11月  
    In patients with acute myocardial infarction (MI), heart failure (HF) is one of the most common complications that is associated with a significant burden of mortality and healthcare resources. The clinical benefits of key HF drugs, the so-called “4 pillars” or “fantastic 4”, namely β-blockers, mineralocorticoid receptor antagonists, angiotensin receptor-neprilysin inhibitor, and sodium-glucose cotransporter 2 inhibitors, have been established in patients with HF with reduced ejection fraction, whereas the effects of these drugs are not comprehensively appreciated in patients with acute MI. This review summarizes current evidence on pharmacological and device-based interventions for preventing HF after acute MI.
  • Yoshiyasu Minami, Junya Ako, Kenichi Tsujita, Hiroyoshi Yokoi, Yuji Ikari, Yoshihiro Morino, Yoshio Kobayashi, Ken Kozuma
    Cardiovascular Intervention and Therapeutics 39(3) 223-233 2024年7月  
    Abstract: Non-culprit lesion-related coronary events are a significant concern in patients with coronary artery disease (CAD) undergoing coronary intervention. Since several studies using intra-coronary imaging modalities have reported a high prevalence of vulnerable plaques in non-culprit lesions at the initial coronary event, the immediate stabilization of these plaques by intensive pharmacological regimens may contribute to the reduction in the adverse events. Although current treatment guidelines recommend the titration of statin and other drugs to attain the treatment goal of low-density lipoprotein cholesterol (LDL-C) level in patients with CAD, the early prescription of strong LDL-C lowering drugs with more intensive regimen may further reduce the incidence of recurrent cardiovascular events. In fact, several studies with intensive regimen have demonstrated a higher percentage of patients with the attainment of LDL-C treatment goal in the early phase following discharge. In addition to many imaging studies showing plaque stabilization by LDL-C lowering drugs, several recent reports have shown the efficacy of early statin and proprotein convertase subtilisin/kexin type 9 inhibitors on the immediate stabilization of non-culprit coronary plaques. To raise awareness regarding this important concept of immediate plaque stabilization and subsequent reduction in the incidence of recurrent coronary events, the term ‘Drug Intervention’ has been introduced and gradually applied in the clinical field, although a clear definition is lacking. The main target of this concept is patients with acute coronary syndrome as a higher prevalence of vulnerable plaques in non-culprit lesions in addition to the worse clinical outcomes has been reported in recent imaging studies. In this article, we discuss the backgrounds and the concept of drug intervention. Graphical Abstract: (Figure presented.)
  • AOKI Shuhei, TAKAOKA Hiroyuki, KINOSHITA Makiko, YASHIMA Satomi, SUZUKI Katsuya, NISHIKAWA Yusei, NOGUCHI Yoshitada, YOSHIDA Kazuki, SASAKI Haruka, SUZUKI Noriko, KOBAYASHI Yoshio
    日本循環器学会学術集会(Web) 88th 2024年  
  • 與子田一輝, 與子田一輝, 佐々木晴香, 佐々木晴香, 佐々木晴香, 高岡浩之, 鎌田知子, 川崎健治, 江口紀子, 江口紀子, 江口紀子, 小林欣夫, 松下一之, 松下一之
    超音波医学 Supplement 51 2024年  
  • YASHIMA Satomi, TAKAOKA Hiroyuki, TAKAHASHI Manami, KINOSHITA Makiko, AOKI Shuhei, KOBAYASHI Yoshio
    日本循環器学会学術集会(Web) 87th 2023年  
もっとみる

所属学協会

 10
もっとみる

共同研究・競争的資金等の研究課題

 6
もっとみる
一覧へ戻る